Last reviewed · How we verify

Spikevax Omicron XBB.1.5 — Competitive Intelligence Brief

Spikevax Omicron XBB.1.5 (Spikevax Omicron XBB.1.5) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: mRNA vaccine. Area: Immunology / Infectious Disease.

marketed mRNA vaccine SARS-CoV-2 spike protein (XBB.1.5 variant) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Spikevax Omicron XBB.1.5 (Spikevax Omicron XBB.1.5) — Jules Bordet Institute. Spikevax Omicron XBB.1.5 is an mRNA vaccine that instructs cells to produce the spike protein of the XBB.1.5 Omicron variant of SARS-CoV-2, triggering an immune response to protect against COVID-19 infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Spikevax Omicron XBB.1.5 TARGET Spikevax Omicron XBB.1.5 Jules Bordet Institute marketed mRNA vaccine SARS-CoV-2 spike protein (XBB.1.5 variant)
Comirnaty Original/Omicron BA.4-5 Comirnaty Original/Omicron BA.4-5 Jules Bordet Institute marketed mRNA vaccine SARS-CoV-2 spike protein (original strain and Omicron BA.4-5 variants)
BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg bnt162b2-bivalent-original-omicron-ba-4-ba-5-30-mcg Pfizer marketed mRNA vaccine Spike protein
Comirnaty Original/Omicron BA.1 Comirnaty Original/Omicron BA.1 Jules Bordet Institute marketed mRNA vaccine SARS-CoV-2 spike protein (original strain and Omicron BA.1 variant)
mRNA-1273 vaccine mRNA-1273 vaccine University Health Network, Toronto marketed mRNA vaccine SARS-CoV-2 spike protein
COMIRNATY - BioNTech Manufacturing GmbH COMIRNATY - BioNTech Manufacturing GmbH Jens D Lundgren, MD marketed mRNA vaccine SARS-CoV-2 spike protein (S protein)
mRNA-1273 Variant-containing Formulation mRNA-1273 Variant-containing Formulation ModernaTX, Inc. marketed mRNA vaccine SARS-CoV-2 spike protein (variant-specific)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (mRNA vaccine class)

  1. Pfizer · 12 drugs in this class
  2. ModernaTX, Inc. · 11 drugs in this class
  3. BioNTech SE · 5 drugs in this class
  4. Jules Bordet Institute · 5 drugs in this class
  5. Tan Tock Seng Hospital · 2 drugs in this class
  6. Clover Biopharmaceuticals AUS Pty · 1 drug in this class
  7. CanSino Biologics Inc. · 1 drug in this class
  8. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
  9. CSPC Megalith Biopharmaceutical Co.,Ltd. · 1 drug in this class
  10. Jens D Lundgren, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Spikevax Omicron XBB.1.5 — Competitive Intelligence Brief. https://druglandscape.com/ci/spikevax-omicron-xbb-1-5. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: